Kinome profiling identifies druggable targets for novel human cytomegalovirus (HCMV) antivirals

Molecular and Cellular Proteomics

Volumn 16, Issue 4, 2017, Pages S263-S276

  Arend, Kyle C ^a,b   Lenarcic, Erik M ^a,b   Vincent, Heather A ^a,b   Rashid, Naim ^b,c   Lazear, Eric ^a,b   McDonald, Ian M ^a   Gilbert, Thomas S K ^a   East, Michael P ^a   Herring, Laura E ^a,c   Johnson, Gary L ^a   Graves, Lee M ^a,c   Moorman, Nathaniel J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; ANTIVIRUS AGENT; BIRABRESIB; DINACICLIB; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR B4; INITIATION FACTOR 4B; MRT 67307; N [4 [(2 AMINO 3 CHLORO 4 PYRIDINYL)OXY] 3 FLUOROPHENYL] 4 ETHOXY 1 (4 FLUOROPHENYL) 2(1H) OXONICOTINAMIDE; OTSSP 167; PF 3814735; PROTEIN TYROSINE KINASE; RABUSERTIB; SARACATINIB; SBI 0206965; SOTRASTAURIN; TG 003; TIVANTINIB; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNC 2025; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG COST; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IC50; LD50; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MASS SPECTROMETRY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS STRAIN; CELL CULTURE; CYTOMEGALOVIRUS; DRUG EFFECTS; DRUG REPOSITIONING; METABOLISM; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS; DRUG REPOSITIONING; HUMANS; MASS SPECTROMETRY; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 85017121791     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M116.065375     Document Type: Article

References (87)

1. DiMasi, J. A., Grabowski, H. G., and Hansen, R. W. (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 47, 20-33
2. Marschall, M., and Stamminger, T. (2009) Molecular targets for antiviral therapy of cytomegalovirus infections. Future Microbiol. 4, 731-742
3. van der Bij, W., and Speich, R. (2001) Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin. Infect. Dis. 33, S32-S37
4. Griffiths, P., Baraniak, I., and Reeves, M. (2015) The pathogenesis of human cytomegalovirus. J. Pathol. 235, 288-297
5. Jacobsen, T., and Sifontis, N. (2010) Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am. J. Health Syst. Pharm. 67, 1417-1425
6. Eid, A. J., and Razonable, R. R. (2010) New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 70, 965-981
7. Munger, J., Bajad, S. U., Coller, H. A., Shenk, T., and Rabinowitz, J. D. (2006) Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog. 2, e132
8. Munger, J., Bennett, B. D., Parikh, A., Feng, X. J., McArdle, J., Rabitz, H. A., Shenk, T., and Rabinowitz, J. D. (2008) Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol. 26, 1179-1186
9. Shenk, T., and Alwine, J. C. (2014) Human Cytomegalovirus: Coordinating Cellular Stress, Signaling, and Metabolic Pathways. Annu. Rev. Virol. 1, 355-374
10. Bain, M., and Sinclair, J. (2007) The S phase of the cell cycle and its perturbation by human cytomegalovirus. Rev. Med. Virol. 17, 423-434
11. Sanchez, V., and Spector, D. H. (2008) Subversion of cell cycle regulatory pathways. Curr. Top. Microbiol. Immunol. 325, 243-262
12. Yurochko, A. D. (2008) Human cytomegalovirus modulation of signal transduction. Curr. Top. Microbiol. Immunol. 325, 205-220
13. Vincent, H. A., Ziehr, B., and Moorman, N. J. (2016) Human cytomegalovirus strategies to maintain and promote mRNA translation. Viruses 8, 97
14. Walsh, D., Mathews, M. B., and Mohr, I. (2013) Tinkering with translation: protein synthesis in virus-infected cells. Cold Spring Harb. Perspect. Biol. 5, a012351
15. Beelontally, R., Wilkie, G. S., Lau, B., Goodmaker, C. J., Ho, C. M., Swanson, C. M., Deng, X., Wang, J., Gray, N. S., Davison, A. J., and Strang, B. L. (2017) Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins. Antiviral Res. 138, 61-67
16. Khan, A. S., Murray, M. J., Ho, C. M., Zuercher, W. J., Reeves, M. B., and Strang, B. L. (2017) High throughput screening of a GlaxoSmithKline protein kinase inhibitor set identifies an inhibitor of human cytomegalovirus replication that prevents CREB and histone H3 post-translational modification. J. Gen. Virol.
17. Mercorelli, B., Luganini, A., Nannetti, G., Tabarrini, O., Palu, G., Gribaudo, G., and Loregian, A. (2016) Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication. Cell Chem. Biol. 23, 340-351
18. Ziehr, B., Vincent, H. A., and Moorman, N. J. (2016) Human cytomegalovirus pTRS1 and pIRS1 antagonize protein kinase R to facilitate virus replication. J. Virol. 90, 3839-3848
19. Johnson, R. A., Wang, X., Ma, X. L., Huong, S. M., and Huang, E. S. (2001) Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J. Virol. 75, 6022-6032
20. Moorman, N. J., Cristea, I. M., Terhune, S. S., Rout, M. P., Chait, B. T., and Shenk, T. (2008) Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex. Cell Host Microbe 3, 253-262
21. McArdle, J., Moorman, N. J., and Munger, J. (2012) HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication. PLoS Pathog. 8, e1002502
22. Terry, L. J., Vastag, L., Rabinowitz, J. D., and Shenk, T. (2012) Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. Proc. Natl. Acad. Sci. U.S.A. 109, 3071-3076
23. Moorman, N. J., and Shenk, T. (2010) Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J. Virol. 84, 5260-5269
24. Perwitasari, O., Yan, X., O'Donnell, J., Johnson, S., and Tripp, R. A. (2015) Repurposing kinase inhibitors as antiviral agents to control influenza a virus replication assay. Drug Dev. Technol. 13, 638-649
25. Mohr, E. L., McMullan, L. K., Lo, M. K., Spengler, J. R., Bergeron, E., Albarino, C. G., Shrivastava-Ranjan, P., Chiang, C. F., Nichol, S. T., Spiropoulou, C. F., and Flint, M. (2015) Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses. Antiviral Res. 120, 40-47
26. Marty, F. M., Bryar, J., Browne, S. K., Schwarzberg, T., Ho, V. T., Bassett, I. V., Koreth, J., Alyea, E. P., Soiffer, R. J., Cutler, C. S., Antin, J. H., and Baden, L. R. (2007) Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 110, 490-500
27. Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., Usary, J., Kuan, P. F., Smalley, D. M., Major, B., He, X., Hoadley, K. A., Zhou, B., Sharpless, N. E., Perou, C. M., Kim, W. Y., Gomez, S. M., Chen, X., Jin, J., Frye, S. V., Earp, H. S., Graves, L. M., and Johnson, G. L. (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321
28. Oppermann, F. S., Gnad, F., Olsen, J. V., Hornberger, R., Greff, Z., Keri, G., Mann, M., and Daub, H. (2009) Large-scale proteomics analysis of the human kinome. Mol. Cell. Proteomics 8, 1751-1764
29. Daub, H. (2015) Quantitative proteomics of kinase inhibitor targets and mechanisms. ACS Chem. Biol. 10, 201-212
30. Graves, L. M., Duncan, J. S., Whittle, M. C., and Johnson, G. L. (2013) The dynamic nature of the kinome. Biochem. J. 450, 1-8
31. Ruprecht, B., Zecha, J., Heinzlmeir, S., Medard, G., Lemeer, S., and Kuster, B. (2015) Evaluation of Kinase Activity Profiling Using Chemical Proteomics. ACS Chem. Biol. 10, 2743-2752
32. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044
33. Wissing, J., Jansch, L., Nimtz, M., Dieterich, G., Hornberger, R., Keri, G., Wehland, J., and Daub, H. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol. Cell. Proteomics 6, 537-547
34. Zawistowski, J. S., Graves, L. M., and Johnson, G. L. (2014) Assessing adaptation of the cancer kinome in response to targeted therapies. Biochem. Soc. Trans. 42, 765-769
35. Stuhlmiller, T. J., Miller, S. M., Zawistowski, J. S., Nakamura, K., Beltran, A. S., Duncan, J. S., Angus, S. P., Collins, K. A., Granger, D. A., Reuther, R. A., Graves, L. M., Gomez, S. M., Kuan, P. F., Parker, J. S., Chen, X., Sciaky, N., Carey, L. A., Earp, H. S., Jin, J., and Johnson, G. L. (2015) Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 11, 390-404
36. Johnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., and Graves, L. M. (2014) Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin. Cancer Res. 20, 2516-2522
37. Graves, L. M., and Litchfield, D. W. (2011) "Going KiNativ": probing the native kinome. Chem. Biol. 18, 683-684
38. Miao, W., Xiao, Y., Guo, L., Jiang, X., Huang, M., and Wang, Y. (2016) A high-throughput targeted proteomic approach for comprehensive profiling of methylglyoxal-induced perturbations of the human kinome. Anal. Chem. 88, 9773-9779
39. Cooper, M. J., Cox, N. J., Zimmerman, E. I., Dewar, B. J., Duncan, J. S., Whittle, M. C., Nguyen, T. A., Jones, L. S., Ghose Roy, S., Smalley, D. M., Kuan, P. F., Richards, K. L., Christopherson, R. I., Jin, J., Frye, S. V., Johnson, G. L., Baldwin, A. S., and Graves, L. M. (2013) Application of multiplexed kinase inhibitor beads to study kinome adaptations in drugresistant leukemia. PLoS ONE 8, e66755
40. Kurimchak, A. M., Shelton, C., Duncan, K. E., Johnson, K. J., Brown, J., O'Brien, S., Gabbasov, R., Fink, L. S., Li, Y., Lounsbury, N., Abou-Gharbia, M., Childers, W. E., Connolly, D. C., Chernoff, J., Peterson, J. R., and Duncan, J. S. (2016) Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 16, 1273-1286
41. Werth, E. G., McConnell, E. W., Gilbert, T. S., Couso Lianez, I., Perez, C. A., Manley, C. K., Graves, L. M., Umen, J. G., and Hicks, L. M. (2016) Probing the global kinome and phosphoproteome in Chlamydomonas reinhardtii via sequential enrichment and quantitative proteomics. Plant J.
42. Kouznetsova, J., Sun, W., Martinez-Romero, C., Tawa, G., Shinn, P., Chen, C. Z., Schimmer, A., Sanderson, P., McKew, J. C., Zheng, W., and Garcia-Sastre, A. (2014) Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg. Microbes Infect. 3, e84
43. Johansen, L. M., DeWald, L. E., Shoemaker, C. J., Hoffstrom, B. G., Lear-Rooney, C. M., Stossel, A., Nelson, E., Delos, S. E., Simmons, J. A., Grenier, J. M., Pierce, L. T., Pajouhesh, H., Lehar, J., Hensley, L. E., Glass, P. J., White, J. M., and Olinger, G. G. (2015) A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci. Transl. Med. 7, 290ra289
44. Wang, D., Bresnahan, W., and Shenk, T. (2004) Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc. Natl. Acad. Sci. U.S.A. 101, 16642-16647
45. Moorman, N. J., Sharon-Friling, R., Shenk, T., and Cristea, I. M. (2010) A targeted spatial-temporal proteomics approach implicates multiple cellular trafficking pathways in human cytomegalovirus virion maturation. Mol. Cell. Proteomics 9, 851-860
46. Arend, K. C., Ziehr, B., Vincent, H. A., and Moorman, N. J. (2016) Multiple transcripts encode full-length human cytomegalovirus IE1 and IE2 proteins during lytic infection. J. Virol. 90, 8855-8865
47. Charles E. McCulloch, S. R. S., John M. Neuhaus. (2008) Generalized linear mixed models., Wiley
48. Bates, D., et al. (2014) lme4: Linear mixed-effects models using Eigen and S4, R package version 1.7
49. Clough, T., Thaminy, S., Ragg, S., Aebersold, R., and Vitek, O. (2012) Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs. BMC Bioinformatics 13, S6
50. Kuznetsova, A., Per Bruun Brockhoff and Rune Haubo Bojesen Christensen. (2015) Package 'lmerTest'. R package version
51. Benjamini, Y., and Yosef Hochberg. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statistical Soc. 289-300
52. Lenarcic, E. M., Ziehr, B. J., and Moorman, N. J. (2015) An unbiased proteomics approach to identify human cytomegalovirus RNA-associated proteins. Virology 481, 13-23
53. Zhu, H., Shen, Y., and Shenk, T. (1995) Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol. 69, 7960-7970
54. Romanowski, M. J., and Shenk, T. (1997) Characterization of the human cytomegalovirus irs1 and trs1 genes: a second immediate-early transcription unit within irs1 whose product antagonizes transcriptional activation. J. Virol. 71, 1485-1496
55. Silva, M. C., Yu, Q. C., Enquist, L., and Shenk, T. (2003) Human cytomegalovirus UL99-encoded pp28 is required for the cytoplasmic envelopment of tegument-associated capsids. J. Virol. 77, 10594-10605
56. Ziehr, B., Lenarcic, E., Cecil, C., and Moorman, N. J. (2016) The eIF4AIII RNA helicase is a critical determinant of human cytomegalovirus replication. Virology 489, 194-201
57. Lenarcic, E. M., Ziehr, B., De Leon, G., Mitchell, D., and Moorman, N. J. (2014) Differential role for host translation factors in host and viral protein synthesis during human cytomegalovirus infection. J. Virol. 88, 1473-1483
58. Sinzger, C., Hahn, G., Digel, M., Katona, R., Sampaio, K. L., Messerle, M., Hengel, H., Koszinowski, U., Brune, W., and Adler, B. (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 89, 359-368
59. Kania, A., and Klein, R. (2016) Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat. Rev. Mol. Cell Biol. 17, 240-256
60. Massague, J. (2012) TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630
61. Kig, C., Beullens, M., Beke, L., Van Eynde, A., Linders, J. T., Brehmer, D., and Bollen, M. (2013) Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells. J. Biol. Chem. 288, 24200-24212
62. Ganguly, R., Hong, C. S., Smith, L. G., Kornblum, H. I., and Nakano, I. (2014) Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers. Mol. Cancer Therap. 13, 1393-1398
63. Beullens, M., Vancauwenbergh, S., Morrice, N., Derua, R., Ceulemans, H., Waelkens, E., and Bollen, M. (2005) Substrate specificity and activity regulation of protein kinase MELK. J. Biol. Chem. 280, 40003-40011
64. Yang, Y., Begley, M., Huang, H. T., Lako, A., Eck, M. J., Gray, N. S., Mitchison, T. J., Cantley, L. C., and Zhao, J. J. (2016) Mitotic MELKeIF4B signaling controls protein synthesis and tumor cell survival. Proc. Natl. Acad. Sci. U.S.A. 113, 9810-9815
65. Wang, Y., Lee, Y. M., Baitsch, L., Huang, A., Xiang, Y., Tong, H., Lako, A., Von, T., Choi, C., Lim, E., Min, J., Li, L., Stegmeier, F., Schlegel, R., Eck, M. J., Gray, N. S., Mitchison, T. J., and Zhao, J. J. (2014) MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. eLife 3, e01763
66. Huang, E. S. (1975) Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid. J. Virol. 16, 1560-1565
67. Overall, J. C., Jr, Kern, E. R., and Glasgow, L. A. (1976) Effective antiviral chemotherapy in cytomegalovirus infection of mice. J. Infect. Dis. 133, A237-A244
68. Ember, S. W., Zhu, J. Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., and Schonbrunn, E. (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 9, 1160-1171
69. Coude, M. M., Braun, T., Berrou, J., Dupont, M., Bertrand, S., Masse, A., Raffoux, E., Itzykson, R., Delord, M., Riveiro, M. E., Herait, P., Baruchel, A., Dombret, H., and Gardin, C. (2015) BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 6, 17698-17712
70. Asangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y., and Chinnaiyan, A. M. (2016) BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol. Cancer Res. 14, 324-331
71. Boi, M., Gaudio, E., Bonetti, P., Kwee, I., Bernasconi, E., Tarantelli, C., Rinaldi, A., Testoni, M., Cascione, L., Ponzoni, M., Mensah, A. A., Stathis, A., Stussi, G., Riveiro, M. E., Herait, P., Inghirami, G., Cvitkovic, E., Zucca, E., and Bertoni, F. (2015) The BET Bromodomain Inhibitor OTX015 Affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin. Cancer Res. 21, 1628-1638
72. Xiaofei, E., and Kowalik, T. F. (2014) The DNA damage response induced by infection with human cytomegalovirus and other viruses. Viruses 6, 2155-2185
73. Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y. A., Yu, X., Nagata, A., VanArsdale, T., and Murray, B. W. (2016) Spectrum and degree of CDK drug interactions predicts clinical performance. Mol. Cancer Therap. 15, 2273-2281
74. Chung, S., Suzuki, H., Miyamoto, T., Takamatsu, N., Tatsuguchi, A., Ueda, K., Kijima, K., Nakamura, Y., and Matsuo, Y. (2012) Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget 3, 1629-1640
75. Mar, E. C., Cheng, Y. C., and Huang, E. S. (1983) Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 24, 518-521
76. Stern-Ginossar, N., Weisburd, B., Michalski, A., Le, V. T., Hein, M. Y., Huang, S. X., Ma, M., Shen, B., Qian, S. B., Hengel, H., Mann, M., Ingolia, N. T., and Weissman, J. S. (2012) Decoding human cytomegalovirus. Science 338, 1088-1093
77. Weekes, M. P., Tomasec, P., Huttlin, E. L., Fielding, C. A., Nusinow, D., Stanton, R. J., Wang, E. C., Aicheler, R., Murrell, I., Wilkinson, G. W., Lehner, P. J., and Gygi, S. P. (2014) Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157, 1460-1472
78. Johnson, R. A., Ma, X. L., Yurochko, A. D., and Huang, E. S. (2001) The role of MKK1/2 kinase activity in human cytomegalovirus infection. J. Gen. Virol. 82, 493-497
79. Cojohari, O., Peppenelli, M. A., and Chan, G. C. (2016) Human cytomegalovirus induces an atypical activation of Akt to stimulate the survival of short-lived monocytes. J. Virol. 90, 6443-6452
80. Peppenelli, M. A., Arend, K. C., Cojohari, O., Moorman, N. J., and Chan, G. C. (2016) Human cytomegalovirus stimulates the synthesis of select Akt-dependent antiapoptotic proteins during viral entry to promote survival of infected monocytes. J. Virol. 90, 3138-3147
81. Sanchez, V., and Spector, D. H. (2006) Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J. Virol. 80, 5886-5896
82. Zydek, M., Hagemeier, C., and Wiebusch, L. (2010) Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle. PLoS Pathog. 6, e1001096
83. Pasquale, E. B. (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10, 165-180
84. Chan, G., Bivins-Smith, E. R., Smith, M. S., and Yurochko, A. D. (2008) Transcriptome analysis of NF-kappaB- and phosphatidylinositol 3-kinase-regulated genes in human cytomegalovirus-infected monocytes. J. Virol. 82, 1040-1046
85. Zhang, F., Wang, H., Wang, X., Jiang, G., Liu, H., Zhang, G., Wang, H., Fang, R., Bu, X., Cai, S., and Du, J. (2016) TGF-beta induces M2-like macrophage polarization via SNAIL-mediated suppression of a proinflammatory phenotype. Oncotarget
86. Wang, Y., Begley, M., Li, Q., Huang, H. T., Lako, A., Eck, M. J., Gray, N. S., Mitchison, T. J., Cantley, L. C., and Zhao, J. J. (2016) Mitotic MELKeIF4B signaling controls protein synthesis and tumor cell survival. Proc. Natl. Acad. Sci. U.S.A. 113, 9810-9815
87. Ji, W., Arnst, C., Tipton, A. R., Bekier, M. E., 2nd, Taylor, W. R., Yen, T. J., and Liu, S. T. (2016) OTSSP167 Abrogates mitotic checkpoint through inhibiting multiple mitotic kinases. PLoS ONE 11, e0153518